Vaxxinity Inc (VAXX) AI Stock Analysis

• Market Cap: $141.00
• Dividend Yield: N/A
• Average Volume (3M): 5.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 291.62
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 126,784,680
• 10 Day Avg. Volume: 3,116
• 30 Day Avg. Volume: 5,294
• PEG Ratio: 18.90
• Price to Book (P/B): 8.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.85
• Enterprise Value/Market Cap: 90.59K
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -7.82
• Enterprise Value/Ebitda: -0.24
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

No summary available

Positive Factors

Innovative Vaccine Platform

Vaxxinity's innovative platform for developing vaccines positions it well in the biotechnology sector, potentially transforming treatment landscapes for chronic diseases.

Negative Factors

High Financial Leverage

High financial leverage can strain Vaxxinity's financial stability, increasing risk and potentially limiting its ability to invest in growth opportunities.

Vaxxinity Inc Business Overview & Revenue Model

Company Description

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amy...

Read more

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amy...

How the Company Makes Money

Vaxxinity Inc generates revenue primarily through the development and commercialization of its vaccine candidates. The company aims to advance its pipeline of vaccine products through clinical trials and regulatory approvals, ultimately leading to...

Read more

Vaxxinity Inc generates revenue primarily through the development and commercialization of its vaccine candidates. The company aims to advance its pipeline of vaccine products through clinical trials and regulatory approvals, ultimately leading to...

Vaxxinity Inc Financial Statement Overview

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	0.00	66.00K	557.00K	0.00
Gross Profit	-2.23M	-1.68M	-1.87M	505.00K	-107.00K
EBITDA	-54.00M	-73.02M	-135.23M	-38.06M	-13.58M
Net Income	-56.93K	-75.21M	-137.18M	-39.96M	-14.22M
Balance Sheet
Total Assets	44.31M	106.40M	166.67M	50.14M	1.59M
Cash, Cash Equivalents and Short-Term Investments	30.39M	86.83M	144.88M	31.14M	476.00K
Total Debt	15.17M	14.55M	10.70M	38.30M	14.33M
Total Liabilities	30.90M	44.22M	38.05M	137.52M	50.11M
Stockholders Equity	13.41M	62.18M	128.62M	-87.38M	-48.51M
Cash Flow
Free Cash Flow	-58.04M	-57.79M	-82.31M	-35.39M	-12.27M
Operating Cash Flow	-57.24M	-55.93M	-80.99M	-33.91M	-12.27M
Investing Cash Flow	28.84M	-54.39M	-1.32M	-1.48M	0.00
Financing Cash Flow	-1.14M	-167.00K	196.17M	66.11M	11.14M

Vaxxinity Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VAXX	―	$141.00	―	-0.42%	―	―	―
EVAX	58 Neutral	$31.53M	-3.95	-61.62%	―	4455.07%	77.31%
SCNI	49 Neutral	$2.08M	-0.24	―	―	178.82%	-4121.10%
GRI	43 Neutral	$3.44M	-0.15	-381.74%	―	―	98.22%
AIM	41 Neutral	$4.85M	-0.13	382.28%	―	-41.05%	57.35%